PROK2: A Potential Drug Target and Biomarker (G60675)

Target Name: PROK2

NCBI ID: G60675

PROK2

PROK2: A Potential Drug Target and Biomarker

Prokineticin 2 (PROK2) is a protein that is expressed in various tissues throughout the body, including the heart, lungs, and kidneys. It is a member of the P2Y12 receptor tyrosine kinase family and is involved in the regulation of platelet function and vascular remodeling. PROK2 has been identified as a potential drug target and biomarker for various cardiovascular diseases, including hypertension, heart failure, and atrial fibrillation.

The P2Y12 receptor tyrosine kinase family is a subfamily of G protein-coupled receptors (GPCRs) that are involved in the regulation of extracellular signaling pathways, including platelet function and vascular remodeling. The P2Y12 receptor tyrosine kinase family consists of four isoforms, including PROK2, PROK4, PROK6, and PROK8. These isoforms are differentially expressed in various tissues and are involved in the regulation of different physiological processes, including platelet aggregation, vascular remodeling, and cancer progression.

PROK2 is a 12-kDa protein that is expressed in various tissues, including the heart, lungs, and kidneys. It is a member of the P2Y12 receptor tyrosine kinase family and is involved in the regulation of platelet function and vascular remodeling. PROK2 has been shown to play a role in the regulation of platelet aggregation and the aggregation of injured blood vessels. It has also been shown to be involved in the regulation of vascular remodeling and the development of atherosclerosis.

In addition to its role in platelet function and vascular remodeling, PROK2 has also been shown to be involved in the regulation of various signaling pathways that are involved in cancer progression. For example, PROK2 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and growth. Additionally, PROK2 has been shown to be involved in the regulation of the TGF-β signaling pathway, which is involved in the regulation of cell growth and differentiation.

As a potential drug target, PROK2 has been shown to have a number of potential therapeutic benefits. For example, PROK2 has been shown to be involved in the regulation of platelet aggregation, which is involved in the development of cardiovascular diseases such as hypertension and heart failure. Additionally, PROK2 has been shown to be involved in the regulation of vascular remodeling, which is involved in the development of atherosclerosis and other cardiovascular diseases.

In addition to its potential therapeutic benefits, PROK2 has also been shown to be a potential biomarker for various cardiovascular diseases. For example, PROK2 has been shown to be involved in the regulation of platelet function, which is involved in the risk of cardiovascular disease. Additionally, PROK2 has been shown to be involved in the regulation of vascular remodeling, which is involved in the risk of cardiovascular disease.

Overall, PROK2 is a protein that is involved in the regulation of platelet function and vascular remodeling. It has been shown to play a role in the regulation of various physiological processes, including platelet aggregation and vascular remodeling. PROK2 is a potential drug target and biomarker for various cardiovascular diseases, including hypertension, heart failure, and atrial fibrillation. Further research is needed to fully understand the role of PROK2 in these diseases and to develop effective treatments.

Protein Name: Prokineticin 2

Functions: May function as an output molecule from the suprachiasmatic nucleus (SCN) that transmits behavioral circadian rhythm. May also function locally within the SCN to synchronize output. Potently contracts gastrointestinal (GI) smooth muscle

The "PROK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PROK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets